New Kit Shatters 3D Cell Culture Barrier, Aims to Accelerate Therapies

SEATTLE, WA and TELFORD, PA – February 05, 2026 – A major bottleneck in advanced medical research may have been broken with the launch of a new technology designed to streamline the genetic modification of stem cells in complex 3D environments. Pluristyx, a specialist in induced pluripotent stem cell (iPSC) technology, and Solesis, a leader in applied biomaterials, today announced the commercial launch of their PluriForm™-GFP-3D Transfection Kit, a product poised to fundamentally change how scientists approach organoid research and the development of cell-based therapies.

The kit promises to solve a long-standing problem that has plagued laboratories for years: the difficulty of efficiently and safely introducing genetic material into iPSCs grown in 3D suspension cultures. The companies claim the all-in-one kit achieves an unprecedented "nearly 100% transfection efficiency," a figure that stands in stark contrast to the often low and inconsistent results of existing methods.

A Breakthrough for a Stubborn Scientific Hurdle

For years, researchers have struggled to genetically engineer iPSCs in the dynamic, three-dimensional aggregates required to form organoids—miniature, lab-grown organs used to model diseases and test new drugs. Traditional transfection methods, such as chemical reagents or electroporation, often prove to be a frustrating trade-off. They can be highly toxic to the sensitive stem cells, leading to widespread cell death, or they deliver genetic material with low efficiency, sometimes below 5%, rendering experiments unreliable and difficult to reproduce. Furthermore, the physical process can damage the delicate cellular aggregates, compromising the integrity of the 3D model.

The PluriForm™-GFP-3D Transfection Kit addresses these challenges head-on by providing a "three-in-one" solution. It combines pre-expanded, high-density iPSCs already adapted for 3D culture with synthetic mRNA that has been pre-complexed to a proprietary transfection reagent. This "thaw and use" configuration is designed to eliminate months of painstaking optimization work for research teams.

"This kit represents a significant leap forward for the field of 3D pluripotent cell culture and organoid research," said Dr. Priya Baraniak, Chief Commercial and Development Officer of Pluristyx, in the official announcement. She noted that the new workflow results in nearly 100% transfection efficiency "without the need for further optimization," enabling researchers to "skip months of development and rapidly generate reproducible results."

The Power of Partnership: Biology Meets Material Science

The breakthrough is the result of a strategic partnership that merges deep biological expertise with advanced material science. Pluristyx brings its industry-leading iPSC technology to the table, including its Ready-to-Differentiate® (RTD®) cell workflow, which provides standardized, high-quality stem cells.

Solesis, on the other hand, contributes the "secret sauce": a proprietary transfection reagent, named PluriGlow™-GFP-3D. While the exact formulation is proprietary, Solesis specializes in developing custom biomaterial platforms for drug delivery. Previous collaborations between the two companies have involved Solesis's Hydralese® biomaterial scaffolds, suggesting the new reagent is built on a sophisticated material science platform designed for gentle yet highly efficient delivery of molecules into cells. This technology ensures the mRNA payload is delivered effectively while minimizing the cytotoxicity that plagues other methods.

"The PluriForm-GFP-3D kit exemplifies the strength of our collaboration with Pluristyx, combining our material science expertise with their biological leadership," stated Marc Hendriks, Vice President of Corporate Development at Solesis. He added that the launch "marks the beginning of a long-term partnership dedicated to delivering a robust portfolio of enabling technologies."

Accelerating the Path from Lab Bench to Patient Bedside

Beyond its immediate impact on basic research, the kit's efficiency and simplicity have significant implications for the entire cell and gene therapy pipeline. The market for these advanced therapies is booming, but progress is often slowed by manufacturing challenges, regulatory hurdles, and high costs. By standardizing a critical early step in the process, the PluriForm kit could dramatically accelerate the development of new treatments.

The reproducibility offered by the kit is particularly crucial for regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which require consistent and well-documented manufacturing processes for therapeutic products. Pluristyx already provides its customers with a significant advantage in this area, offering clinical-grade iPSC lines backed by a registered FDA Drug Master File (DMF). This file streamlines the regulatory pathway for companies using Pluristyx cells as a starting material for therapies. The new kit, built upon this established and regulated platform, is expected to further de-risk and speed up the journey from the laboratory to clinical trials.

The support for scalable suspension and bioreactor workflows is another key feature, addressing the need to move from small-scale research to large-scale manufacturing required for commercializing a successful therapy.

Navigating a Competitive and Growing Market

The launch comes at a time of intense activity and growth in the life sciences sector. The global transfection technologies market was valued at approximately $1.08 billion in 2023 and is projected to more than double to $2.33 billion by 2032. This growth is fueled by relentless progress in regenerative medicine and gene therapy.

The field is competitive, with established players like Sartorius (which acquired transfection specialist Polyplus) and STEMCELL Technologies also offering solutions to streamline cell engineering. However, the PluriForm kit's unique "three-in-one" approach—bundling the cells, the genetic material, and the delivery vehicle into a single, optimized product—sets it apart. It shifts the burden of optimization from the individual researcher to the manufacturer, promising a level of convenience and consistency that could prove highly disruptive. By solving a critical and widely acknowledged pain point with an elegant, integrated solution, Pluristyx and Solesis have positioned themselves to capture a significant share of this expanding market. The kit is available for immediate purchase, allowing scientists to begin leveraging this new capability without delay.